Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

1500 - Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel.

Date

22 Oct 2018

Session

Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care

Topics

Tumour Site

Prostate Cancer

Presenters

Javier Puente

Citation

Annals of Oncology (2018) 29 (suppl_8): viii271-viii302. 10.1093/annonc/mdy284

Authors

J. Puente1, M.J. Mendez Vidal2, M.I. Saez3, A. Font Pous4, I. Duran Martinez5, D. Castellano6, M.J. Juan Fita7, C. Santander8, J.A. Arranz Arija9, A. Sanchez-Hernandez10, B. Mellado11, T. Alonso12, M.A. Gonzalez del Alba Baamonde13, P. Maroto14, M. Lazaro15, E. Esteban16, J.G. Cassinello17, M.A. Climent Duran7

Author affiliations

  • 1 Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 2 Medical Oncology, University Hospital Reina Sofia, 14004 - Cordoba/ES
  • 3 Medical Oncology, H Universitarios Virgen de la victoria y Regional de Málaga, 29010 - Malaga/ES
  • 4 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 5 Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 6 Medical Oncology Department, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 7 Medical Oncology, Fundación Instituto Valenciano de Oncología, 46009 - Valencia/ES
  • 8 Medical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 9 Medical Oncology, Hospital General Universitario Gregorio Marañon, 28007 - Madrid/ES
  • 10 Medical Oncology, Hospital Provincial de Castellón, 12002 - Castellon de la Plana/ES
  • 11 Medical Oncology, Hospital Clinic y Provincial de Barcelona, 8036 - Barcelona/ES
  • 12 Medical Oncology, Hospital Ramón y Cajal, 28034 - Madrid/ES
  • 13 Medical Oncology, Hospital Universitario Son Espases, 7010 - Palma de Mallorca/ES
  • 14 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 08023 - Barcelona/ES
  • 15 Medical Oncology, Complejo Hospitalario Universitario de Vigo, 36312 - Vigo/ES
  • 16 Medical Oncology, Hospital Universitario Central de Asturias, 33006 - Oviedo/ES
  • 17 Medical Oncology, University General Hospital, 19002 - Guadalajara/ES
More

Resources

Abstract 1500

Background

Abiraterone acetate (AA) improves OS and rPFS in asymptomatic/minimally symptomatic mCRPC patients (pts) who are chemotherapy (CT) naïve. Upon progression to this strategy, Docetaxel (D) is currently one of standard treatments. However, the value of maintaining AA along with D despite progression to the former has not been tested yet. ABIDO is a randomized-phase II trial that evaluates efficacy and safety of D + AA vs. D after disease progression to first line AA in mCRPC.

Methods

mCRPC CT naïve pts with no visceral metastases, ECOG PS 0-1, testosterone < 50 ng/dL and adequate, hematologic, hepatic, and renal function were included. The study has two stages. In stage I pts receive AA at the approved regime (AA 1000mg/day+prednisone (P) 5 mgbid) until progressive disease determined by PSCWG2 criteria. Upon progression, in stage II, pts are randomized to receive either three-weekly D + daily AA+P (Arm A) or three-weekly D alone (Arm B).

Results

So far 148 pts have been included and 88 were randomized already. Of those 77 have completed D and have been analyzed (39 in arm A and 38 in Arm B). Median age was 72 y/o, 43% had ECOG 0 and 88% had bone metastases and 16% visceral metastases. Patients received 255 and 274 cycles of D in Arm A and B respectively with a median number of cycles of 7 and 8. Docetaxel median dose intensity was 90% and 92% for each arm and 94% for AA. Nine pts discontinued treatment due to toxicity, 5 in arm A and 4 in arm B. Most frequent G3-4 toxicities per arm (A/B) were: neutropenia (56%; 29%), febrile neutropenia (21%; 8%), diarrhea (10%; 8%), and asthenia (13%; 11%). Most common toxicities all grades per arm were: asthenia (74%; 66%), neutropenia (59%; 34%), alopecia (44%; 45%), nail toxicity (49%; 34%), diarrhea (46%; 42%), neurotoxicity (39%; 42%), nauseas (28%; 26%), mucositis (26%; 29%) and anemia (23%;11%).

Conclusions

In the AA maintenance cohort, more frequent and severe hematological treatment related adverse events (neutropenia, febrile neutropenia and anemia) were observed. No other differences were relevant. Prophylactic G-CSF use is encouraged in all patients. These preliminary data require confirmation once the study is completed.

Clinical trial identification

NCT02036060; EudraCT: 2013-003811-23.

Legal entity responsible for the study

SOGUG: Spanish Oncology Genitourinary Group.

Funding

Janssen-Cilag, S.A.

Editorial Acknowledgement

Juan Luis Sanz, APICES.

Disclosure

J. Puente: Honoraria: Astellas, Bayer, Janssen, Roche, Ipsen; Consulting or advisory role: Astellas, Roche, Ipsen, Pfizer, Bristol-Myers Squibb, Merck sharp & Dohme; Research funding: Astellas. M.J. Mendez Vidal: Consulting: Janssen, Pfizer, Astellas, Sanofi, Bayer, Bristol-Myers Squibb, Novartis, Roche. I. Duran: Honoraria: Bristol-Myers Squibb, Ipsen, Roche; Advisory role: Roche, MSD, Bayer, Bristol-Myers Squibb. A. Sanchez-Hernandez: Honoraria: Sanofi, Astellas, Janssen, Bayer, Roche, Boehringer Ingelheim, Pierre-Fabre, Bristol-Myers Squibb, MSD; Consulting: Sanofi, Astellas, Janssen, Bayer, Roche, Boehringer Ingelheim, Pierre-Fabre, Bristol-Myers Squibb, MSD; Spikers bureau: Sanofi, Astellas, Janssen, Bayer, Roche, Boehringer Ingelheim, Pierre-Fabre, Bristol-Myers Squibb, MSD. T. Alonso: Consulting: Sanofi. M.A. Gonzalez del Alba Baamonde: Consulting: Astellas, Sanofi, Bayer, Janssen, Pfizer, Bristol-Myers Squibb, Eisai, Pierre Fabre. M. Lazaro: Expert testimony: Janssen, Pfizer, Roche. M.A. Climent Duran: Honoraria: Janssen, Astellas, Sanofi, Bayer; Consulting: Janssen, Sanofi, Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.